Why did p53 gene therapy fail in ovarian cancer?

AG Zeimet, C Marth - The lancet oncology, 2003 - thelancet.com
Promising preclinical and clinical data led to the initiation of an international randomised
phase II/III trial of p53 gene-therapy trial for first-line treatment of patients with ovarian …

Clinical trials in recurrent ovarian cancer

M Friedlander, E Trimble, A Tinker, D Alberts… - International Journal of …, 2011 - ijgc.bmj.com
The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was
held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research …

The expression of the regulatory T cell–specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer

D Wolf, AM Wolf, H Rumpold, H Fiegl, AG Zeimet… - Clinical cancer …, 2005 - AACR
Purpose: The forkhead box transcription factor FoxP3 is specifically expressed in T cells with
regulatory properties (Treg). Recently, high numbers of Treg were described to be …

[HTML][HTML] Hopes and failures in front-line ovarian cancer therapy

I Tsibulak, AG Zeimet, C Marth - Critical reviews in oncology/hematology, 2019 - Elsevier
Through the last three decades, the combination of paclitaxel and carboplatin remains the
standard of care chemotherapy in newly diagnosed epithelial ovarian cancer (EOC). Based …

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation

AG Zeimet, D Reimer, M Huszar… - Journal of the …, 2013 - academic.oup.com
Background Despite the excellent prognosis of Fédération Internationale de Gynécologie et
d'Obstétrique (FIGO) stage I, type I endometrial cancers, a substantial number of patients …

DNA hypomethylation and ovarian cancer biology

M Widschwendter, G Jiang, C Woods, HM Müller… - Cancer research, 2004 - AACR
Hypomethylation of some portions of the genome and hypermethylation of others are very
frequent in human cancer. The hypomethylation often involves satellite 2 (Sat2) DNA in the …

Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer

M Widschwendter, J Berger, M Hermann… - Journal of the …, 2000 - academic.oup.com
Background: A growing body of evidence supports the hypotheses that the retinoic acid
receptor β2 (RAR-β2) gene is a tumor suppressor gene and that the chemopreventive …

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer

G Spizzo, P Went, S Dirnhofer, P Obrist, H Moch… - Gynecologic …, 2006 - Elsevier
OBJECTIVE.: Currently available clinical and molecular factors provide still an insufficient
prognostic and predictive assessment for patients with epithelial ovarian cancer (EOC). To …

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of …

J Sehouli, D Stengel, G Oskay-Oezcelik… - Journal of Clinical …, 2008 - ascopubs.org
Purpose The management of recurrent ovarian cancer remains controversial. Single-agent
topotecan is an established treatment option, and preliminary evidence suggests improved …

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

J Pfisterer, CM Shannon, K Baumann, J Rau… - The Lancet …, 2020 - thelancet.com
Background State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based
re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined …